Seroquel Long-Term NIS for Schizophrenia Patients

Completed

• Conditions: Schizophrenia; Schizoaffective Disorder

• Registration Number: NCT00523783
• Lead Sponsor: AstraZeneca

Brief Summary

To assess the efficacy of 24-week treatment with quetiapine in patients with schizophrenia or schizoaffective disorder

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05
• Status Verified: 2007-08
• Study First Submitted: 2007-08-29
• Study First Submitted QC: 2007-08-30
• Study First Posted: 2007-08-31
• Primary Completion: 2007-11
• Study Completion: 2008-05
• Last Update Submitted: 2008-10-03
• Last Update Posted: 2008-10-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent
• The patient suffers from schizophrenia or schizoaffective disorder according to DSM-IV-TR
• The patient is between 18 and 65 years old(extremes included)
• On the basis of physical and neurological examination, medical history, the patient is, in the investigator's opinion, otherwise healthy
• If the subject is a female of childbearing potential, she must be not pregnant or breast-feeding and be using a reliable method of contraception. Reliable methods may include abstinence, hormonal contraceptives (eg,oral contraceptives or long-term injectable or implantable hormonal contraceptives), double-barrier methods (eg, condom and diaphragm, condom and foam, condom and sponge), intrauterine devices, and tubal ligation

Read More

Exclusion Criteria

• The patients who have known hypersensitivity to quetiapine

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Research Site; 🇰🇷 Seoul, Songpa-gu, Korea, Republic of